Heart Failure with Preserved, Mid-Range, and Reduced Ejection Fraction Across Health Care Settings: An Observational Study
Annemarijn R de Boer(Utrecht University), Frans H. Rutten, Arno W. Hoes(University Medical Center Utrecht), Gerard C.M. Linssen(British Heart Foundation), Yvonne van Mourik(Utrecht University), Hans‐Peter Brunner‐La Rocca(Inserm), Ilonca Vaartjes(Utrecht University), Evelien ES van Riet(Utrecht University), Aisha Gohar(Utrecht University), Hester M. den Ruijter(University Medical Center Utrecht), Michiel L. Bots(Utrecht University), Leandra J M Boonman-de Winter, Mark J Valk(Utrecht University), Jasper J. Brugts(Erasmus MC)
Cited by 28
Related Papers
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Guidelines on the management of valvular heart disease (version 2012)
|European Heart Journal|2012|3.6k
ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
|European Heart Journal|2011|3.5k
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
|European Heart Journal|2016|3.2k